Healthcare Industry News: Allergan
News Release - December 14, 2017
Silk Therapeutics Appoints Dr. Rebecca Lacouture to Company PresidentLacouture Assumes Expanded Role to Further the Company's Efforts in Fabric Development
MEDFORD, Mass., Dec. 14, 2017 -- (Healthcare Sales & Marketing Network) -- Silk Therapeutics, Inc., a silk biomaterials company, today announced its board of directors appointed Rebecca Lacouture to company president effective immediately. In this expanded role, Lacouture will drive growth of the company's sustainable process for large-scale production of natural silk in liquid form, while maintaining her position as chief operating officer and a member of the board of directors.
"I am honored the board chose me for this role, especially during a time that is extremely pivotal for Silk Therapeutics as we expand our innovative liquid silk natural chemistry platform into the fabric and textile space," said Lacouture. "In the immediate future, I look forward to driving education around our unique, multi-purpose liquid silk platform and guiding our ever-growing team into the next phase of our business."
Greg Altman, chief executive officer of Silk Therapeutics, praised Rebecca's leadership in business and science. "Over the years, Rebecca has served as the instrumental factor in advancing our liquid silk chemistry platform, allowing us to elevate our overall skincare portfolio formulas and develop a use case for liquid silk in fabric," Altman said. "These achievements ultimately resulted in a successful close of our A Round of funding and the substantial growth of our company, which has doubled in size over the past three months. It's beyond rare to identify a visionary leader in science with naturally superb business abilities. Rebecca is the ideal individual to oversee our business as we infiltrate new sectors within the consumer marketplace and develop our long-term roadmap to success."
Lacouture earned her PhD in Biomedical Engineering from Tufts in 2005, where her doctoral work modeled silk's bioresorption rate in the human body. Prior to co-founding Silk Therapeutics, she served as Senior Director of Clinical Research & Development at Serica Technologies and Senior Director of Research & Development at Allergan Medical. An author of numerous papers on silk science, Lacouture holds several patents related to the structure of silk biomaterials. In 2015, she was named to Boston Business Journal's prestigious 40 Under 40 list.
Silk Therapeutics is recognized for its minimal-ingredient and clean, non-toxic skincare collections that feature pure liquid silk as the active ingredient. Lacouture served as the company's inspiration after battling ovarian cancer at age 27. She sought to create skincare for every woman, even those with ultra-sensitive skin. Her extensive research across product formulations resulted in a completely clean portfolio, eliminating the need for fillers, harsh chemicals and additives.
About Silk Therapeutics
Headquartered in Medford, MA, Silk Therapeutics is dedicated to improving the health of people and the environment through silk innovation. The company is the shared vision of our founders, Drs. Greg Altman and Rebecca Lacouture, foremost experts in natural silk. Drs. Greg and Beck have over two decades of experience as a dynamic team, starting with earning their PhDs in biomedical engineering from Tufts University. Their work at Tufts led them to commercialize the first silk fabric approved for implantation in the human body. They've now created pure liquid silk with the goal of improving the efficacy of consumer goods and textiles, while replacing the unnecessary and sometimes harmful chemicals used to make them.
For more information, please visit www.silktherapeutics.com.
Source: Silk Therapeutics
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.